In 2020, the UK NSC recommended against systematic population screening for prostate cancer of asymptomatic adults because the effectiveness of PSA screening on mortality was unclear and the PSA test may falsely identify individuals who do not have prostate cancer often leading to unnecessary tests, overdiagnosis, and/or treatment with harmful side effects [85]. This evidence concerns the gene KLK3 and Familial prostate cancer.